JDB153 and Serplulimab for advanced pancreatic cancer
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a combination of two drugs, JDB153 and Serplulimab, for people with advanced pancreatic cancer that has stopped responding to standard treatments. It aims to see if this new combination can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced pancreatic cancer that cannot be removed by surgery or has spread to other parts of the body.
- You are between 18 and 75 years old.
- You have tried at least one standard treatment for your cancer, and it has stopped working.
- You are in generally good health, able to do most daily activities on your own.
- You have at least one tumor that can be measured on a CT or MRI scan.
- You have not had treatment with a PD-1 or PD-L1 inhibitor before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy (GnP), an immunotherapy drug (serplulimab), and targeted radiation (SBRT) as a first treatment for locally advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this triple therapy can shrink the tumor and improve outcomes.
This trial tests if adding radiation and an immunotherapy drug (serplulimab) to standard chemotherapy can help people with pancreatic cancer that has come back or spread. It is for those who haven't had prior treatment for advanced disease.
This trial tests a combination of two targeted drugs (serplulimab and bevacizumab) plus two different chemotherapy regimens for people with advanced pancreatic cancer that has worsened after first-line treatment. The goal is to see if this new combination can help shrink tumors or slow the cancer.
This trial tests a combination of chemotherapy plus two targeted drugs (serplulimab and bevacizumab) against chemotherapy alone for pancreatic cancer that cannot be removed by surgery or has spread. This approach may help shrink or stabilize the tumor longer.
This trial tests a combination of a targeted immune therapy (Adebrelimab) with three chemotherapy drugs for people with metastatic pancreatic cancer who haven't had any treatment yet. The goal is to see if this combination can shrink tumors and help people live longer.
This trial tests if adding two targeted drugs (surufatinib and serplulimab) to standard chemotherapy can shrink locally advanced pancreatic cancer enough to allow surgery. It may help people whose cancer hasn't spread and who haven't had prior treatment.
Hear when a new Refractory Pancreatic Ductal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.